Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10739007 | 0.87 | TSHR (0.50) | TSHRGLADGKACYP1A2ALDH1A1 | |
| SCHEMBL134075 | 0.87 | TSHR (0.43) | TSHRDGKACYP1A2ALDH1A1LMNA | |
| SCHEMBL16295140 | 0.85 | DGKA (0.43) | TSHRDGKAALDH1A1LMNA | |
| SCHEMBL8463255 | 0.85 | DGKA (0.43) | TSHRDGKAALDH1A1LMNA | |
| SCHEMBL8465959 | 0.85 | DGKA (0.43) | TSHRDGKAALDH1A1LMNA | |
| SCHEMBL8463526 | 0.85 | DGKA (0.43) | TSHRDGKAALDH1A1LMNA | |
| SCHEMBL4303758 | 0.82 | TSHR (0.45) | TSHRALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL28196127 | 0.81 | CES1 (0.46) | TSHRDGKAALDH1A1LMNA | |
| SCHEMBL4644791 | 0.81 | CAMK2A (0.40) | TSHRDGKACYP1A2KDM4E | |
| SCHEMBL19858487 | 0.79 | DGKA (0.54) | TSHRDGKAALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732413-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732413-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1601669-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080200446-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200446-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-7378518-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378518-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-7208486-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208486-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| CN-1756756-A | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | SCHERING CORP (US) | 2006-04-05 | — | — | CN | disclosed |
| EP-1601669-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004081003-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLETEROLEMIA | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040180861-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180861-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | TSHR 3756/4885GLA 3042/4885DGKA 508/4885 |
| US-20080200446-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | CYP46A1, NPC1L1, PCSK9 | TSHR 4110/4885GLA 1415/4885DGKA 1343/4885 |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | TSHR 3756/4885GLA 3042/4885DGKA 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.